Navigation Links
Qionglai Facility (QLF) Schedules September for GMP Examination
Date:8/18/2014

CHENGDU, China, Aug. 18, 2014 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today provided further updates for the GMP certification regarding the Company's Qionglai Facility (QLF).

Through a series of testing runs using various traditional Chinese medicine (TCM) raw materials at individual production lines, QLF has been preparing for the final GMP examination by the provincial China Food and Drug Administration (CFDA). Further optimization of the production process according to the latest GMP standards were also conducted along with equipment installation and production tests. The manufacturing specialists at TPI's currently operating Longquan plant have also contributed tremendously to the GMP preparation process. TPI has also consulted a designated GMP advisory team for the documentation and compliance for the final GMP examination.

The Company is now scheduling September for the official inspection for both QLF's pre-extraction and formulation facility.

The QLF facility is a combination of both pre-extraction plant for TCM and formulation plant. The pre-extraction facility is designed to process and purify raw materials for TCMs using ethanol or distilled water precipitation, filtration, centrifugation, concentration and purification, which will be further processed for the production of mTCM products at the formulation facility where the final biopharmaceutical, TCM and generic products in the forms of oral liquid, granules, tablets, and capsules are produced.

About QLF

In preparation for the new GMP standards stipulated by the PRC government in early 2011, TPI initiated the process of optimizing the manufacturing facilities in compliance with the new GMP standards. Due to the redesigning of the industrial parks in the suburbs of Chengdu, TPI's manufacturing facility at the Longquan district, east of Chengdu, is scheduled to be relocated to Qionglai city, south of Chengdu, which is designated for pharmaceutical industry. The QLF is approximately 18 miles from the Company's recently completed Jiangchuan macrolide (JCM) facility. The proposed relocation project also includes our TCM pre-extraction plant which is located near the center of Chengdu surrounded by rapidly expanding residential area. The QLF is estimated to be 80 mu or 53,000 square meters. The designed production capacity of QLF is 30% higher than the TPI's currently operating Longquan plant.

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 10 are included in the essential drug list of China. For more information about TPI, please visit: http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email ir@tpi.asia

Tel: +86-28-8551-6696 (Chengdu, China)

Address:

Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China


'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. TPI Provides Progress Update on Qionglai Facility (QLF) Construction
2. TPI Targets Qionglai Facility (QLF) Construction Completion in Mid April
3. TPIs Qionglai Facility (QLF) Construction Completed
4. Delcath Systems, Inc. Secures $20 Million Credit Facility
5. BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility
6. Specialty Silicone Fabricators Inaugurates New State-of-the-Art Facility in Paso Robles
7. Forum Extended Care Services Announces Plans to Move to Larger, State-Of-the-art Facility
8. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
9. Alexza Secures a $20 Million Committed Equity Financing Facility with Azimuth Opportunity, L.P.
10. CMC Biologics Acquires XOMAs Bay Area Manufacturing Facility
11. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and ... Procedure Volumes: Global Analysis (United States, China, Japan, Brazil, ... report to their offering. ... for healthcare business planners, provides surgical procedure volume data ... trends with an in-depth analysis of growth drivers and ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
(Date:6/23/2016)... DIEGO , June 23, 2016 ... programs that address medical conditions resulting from a ... it has appointed Greg Doyle as ... of Leading BioSciences, executive management team and board ... and chief financial officer. He will provide continued ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
Breaking Medicine News(10 mins):